Compounds and Compositions as VHL Ligands and STAT3 Degraders
Summary
USPTO published patent application US20260108613A1 on April 23, 2026, covering compounds and compositions of Formula I or II as VHL ligands and bifunctional degraders for STAT3 protein degradation. The application, filed December 19, 2025, by inventors including Shaomeng Wang and ten co-inventors, lists CPC classifications in A61K, C07D. This is a patent application seeking protection for specific pharmaceutical compounds rather than a granted patent or regulatory action.
“Described herein are compounds or conjugates of Formula I or II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as VHL-binding agents or bifunctional degraders for degrading certain proteins (e.g., STAT3)).”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108613A1 describing compounds and conjugates of Formula I or II as VHL-binding agents and bifunctional degraders for STAT3 protein. The application names eleven inventors and lists pharmaceutical chemistry classifications.
Pharmaceutical and biotechnology companies developing targeted protein degradation therapies should monitor this filing for potential freedom-to-operate implications, particularly those working with VHL-based degradation mechanisms or STAT3 targets.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds and Compositions as VHL Ligands and STAT3 Degraders Uses Thereof
Application US20260108613A1 Kind: A1 Apr 23, 2026
Inventors
Shaomeng Wang, Haibin Zhou, Dimin Wu, Ranjan Kumar Acharyya, Longchuan Bai, Donna McEachern, Hoda Metwally, Mi Wang, Paul Kirchhoff, Jelena Tosovic
Abstract
Described herein are compounds or conjugates of Formula I or II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as VHL-binding agents or bifunctional degraders for degrading certain proteins (e.g., STAT3)).
CPC Classifications
A61K 47/548 C07D 417/14 C07D 487/04 C07D 498/04
Filing Date
2025-12-19
Application No.
19426229
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.